Memoranda of Understanding Signing

Hong Kong, Nov 15, 2023 – The Centre for Immunology & Infection Limited and Hitachi East Asia Limited and collaboration companies have signed two memoranda of understanding to promote a long-time cooperation and formulate partnership in joint research for automation of organoids cell culture and mass production of exosomes in Hong Kong and Mainland China.

Signed by Professor Leo Poon, Managing Director, Centre for Immunology & Infection Limited, Ms Naoko Tsuzuki, Managing Director, Hitachi East Asia Limited, this collaboration aims at improving the treatment of acute lung injury by producing innovative, physiologically relevant, disease platforms for screening therapeutic candidates and developing molecules for treating acute lung injury and providing the highest quality services to help the general public tackle the challenges that come with these illnesses.

“We are excited to collaborate with Hitachi East Asia Limited on this critical research to develop innovative solutions and enhance public health” said Professor Leo Poon, Managing Director, Centre for Immunology & Infection Limited.

“It is our honour to work with the Centre for Immunology & Infection Limited for the commercialization in cell therapy and precision medicine in global market” said Ms Naoko Tsuzuki, Managing Director, Hitachi East Asia Limited.

The two memoranda of understanding also recognize the importance of international collaboration, which is at the heart of the InnoHK scheme that powers the Centre for Immunology & Infection Limited, in developing new automation facilities with latest technologies of the highest standards. It aims to recognize the expansion, modernization, and extension of existing facilities in Hong Kong as a wide field for biotechnology cooperation in the sector of automation of organoids cell culture development and mass production with commercialization. This will be to the benefit of regenerative medicine industry in the Greater Bay Area and beyond.

About Centre for Immunology & Infection Limited

The Centre for Immunology & Infection Limited (C2i) is the fruit of a long-standing partnership between the University of Hong Kong and the Institut Pasteur, using novel technology platforms for biomarker discovery and the development of new vaccine and therapeutic strategies to face public health challenges and make Hong Kong a global centre of excellence for precision medicine and innovative interventions targeting emerging infectious diseases.

The Centre aims to characterize immune responses to infectious agents and their components in a healthy Asian population, develop new vaccine platforms for influenza, new strategies to monitor mosquito-borne viruses and new treatments for lethal respiratory virus infections.

Website: https://www.c2i.hk